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performed. Data collected included: tumour type, technique, 
dose, number of fractions, prescription isodose, acute and 
late toxicity (CTCAE v4.0), local control (LC) and progression 
free survival (PFS). 
 
Results: 12 patients were identified: 8 males and 4 females; 
median age 14.5 years [5-20 years]. Cranial SRS was delivered 
to 9 sites in 7 patients, and extracranial SABR was delivered 
to 8 sites in 5 patients. All patients had a Lansky/ Karnofsky 
score ≥70. All SABR and SRS treatments were performed using 
the Cyberknife® platform; 8 treatments prescribed as a 
single fraction (median dose 19 [18-24] Gy), 4 treatments 
were given in 3 fractions (median dose 28.5 [27-42]Gy) and 5 
treatments in 5 fractions (median dose 30 [30-35]Gy). The 
median prescribing isodose was 79% [70-81%]. For 5 patients 
SRS was delivered post surgical resection with no 
macroscopical residual disease at the time of treatment. The 
treatment for 9 (75%) patients was to previously irradiated 
sites. After a median follow up of 14.5 [0.9-36.2] months 9 
pts (75%) were alive, 2 died from disease progression and 1 
died from unclear cause. MRI response assessment was 
performed at a mean time of 6 [3-17] weeks; 1 patient had a 
complete response, 10 had stable disease (83 %); 1 was not 
assessed due to a rapid clinical deterioration. LC was 100 % 
and 85.7% at 1 and 2 years respectively. PFS was 82.5% at 1 
year and 61.9 % at 2 years. 3 reirradiated patients reported 
symptomatic grade 3 radionecrosis, requiring medical 
therapy. 
 
Conclusion: In this cohort, SABR and SRS with Cyberknife® 
have proven feasible in the subset of paediatric & TYA 
patients with recurrent or oligo-metastatic tumours. It 
achieved good local control even in pre-irradiated patients. 
However optimal patient selection for such a treatment 
approach remains as yet to be determined via an 
international consensus. 
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Purpose or Objective: Particle therapy is not available in our 
country yet, however, quite a few patients are sent abroad 
for such therapy. In the largest health trust, covering a 
population of 2.9 million, 25-40 pediatric patients (< 18 
years) are treated with radiotherapy (RT) yearly. We wanted 
to analyze this group of patient with respect to RT technique 
and diagnosis. 
 
Material and Methods: All pediatric patients treated 
between January 2006 and June 2015 were identified and 
included. The treatment techniques were categorized as 
follows: total body irradiation (TBI), whole CNS RT, 
IMRT/VMAT, stereotactic RT (SRT), 3D conformal RT (CRT), 
kV RT and extracorporal irradiation (ExCRT). Additionally, 
the pediatric patients referred for proton RT abroad were 
registered. 
 
Results: 302 pediatric patients were treated with RT in the 
period. The mean age at treatment were 11.3 ± 4.6 years. 69 
patients (25%) had brain tumors, whereas 50 (18%) and 43 
(16%) patients were diagnosed with lymphoma and leukemia, 
respectively.  
The figure gives the distribution of the treatment techniques 
trough the whole period (upper panel), showing that more 
than 50 % of the patients have been treated with CRT. The 
lower panel in the figure shows the distribution in 2006 (left) 
and 2014 (right), indicating that the proportion of patients 
receiving CRT has decreased from 50 to 38 %. However, the 
number of patients only reduced from 18 in 2006 to 15 in 
2014. The number of patients treated with advanced 
techniques (IMRT/VMAT, SRT) did not change significantly. 
On the other hand, 20 % of the patients were referred for 
proton RT abroad in 2014, while no one received such 
treatment in 2006. The number of patients where the whole 
CNS were treated reduced from 8 (25%) in 2006 to 3 (8%) in 
2014.  
In the whole period 31 patients (10%) were treated with TBI 
and the number of patients per year did not changed 
significantly from 2006 to 2014. 
 
 
 
Conclusion: An official agreement was established with 
proton centers abroad in 2013. The reduction in whole CNS 
treatment throughout the period is due to this agreement. 
Except TBI, kV RT and ExCRT, all the other techniques should 
be replaced with proton RT when such treatment becomes 
available. 
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Purpose or Objective: The Norwegian Breast Cancer Group 
provides national guidelines regarding systemic therapy for 
metastatic breast cancer. While our center adheres to these 
recommendations, use of palliative radiotherapy (PRT) for 
bone metastases is less standardized. Despite general 
recommendations for short course PRT for uncomplicated 
metastases, many physicians prefer ≥10 fractions (long 
course, LC). Our aim was to analyze factors associated with 
prescription of ≥10 fractions. 
 
Material and Methods: This retrospective study included 118 
female patients (all received systemic therapy including 
bone-targeting agents in accordance with national 
guidelines). 
 
Results: Median age was 61 years, and median survival 13 
months. Long-course PRT was prescribed in 60% of patients, 
while 21% had PRT with 8 Gy single fraction to at least one 
target. Reirradiation rate was numerically higher after 8 Gy 
(9%, compared to 5% after LC PRT and 6% after 4 Gy x5, not 
significant). Patients with favorable baseline characteristics 
were significantly more likely to receive LC PRT. These 
characteristics included absence of lung metastases and/or 
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pleural metastases/effusion, normal serum hemoglobin, CRP, 
LDH and albumin (surrogate markers of disease extent), early 
PRT within 6 months from diagnosis of metastases, age <65 
years, and good performance status (ECOG PS). Biological 
subtype (Her2 and hormone receptors), comorbidity and 
reirradiation to a previously treated volume did not correlate 
with fractionation. Rate of LC PRT remained unchanged over 
time. In line with imbalances in prognostic factors, survival 
was significantly longer after LC PRT in univariate analysis. 
However, after correcting imbalances in multivariate analysis 
no survival difference was found. Prognosis was influenced by 
biological subtype (worse for triple negative status), 
extraskeletal disease extent, presence of anemia and 
abnormal CRP. Even patients with PS3 had median survival of 
3 months, which indicates that they life long enough to 
experience clinical benefit after PRT.  
 
Conclusion: The likelihood of receiving LC PRT was 
significantly higher in younger patients, those with good PS, 
limited disease extent, and shorter time interval after 
diagnosis of metastatic disease. Educating physicians about 
these factors might contribute to optimal resource 
utilization. The limited need for reirradiation after single 
fraction PRT might encourage physicians to prescribe this 
convenient regimen, which is also suitable for PS3 patients.  
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Purpose or Objective: To evaluate the efficacy of 
hypofractionated radiotherapy (16 Gy in 2 fractions one week 
apart) in pain relief in patients with complicated bone 
metastases and poor performance status. 
 
Material and Methods: This was a phase 2 multicenter study 
of patients with complicated bone metastases and Karnofsky 
performance status from 30 to 60 who underwent 2 fractions 
of radiotherapy with 8 Gy each one week apart. Pain 
response and quality of life (QOL) were measured using the 
International Consensus on Palliative Radiotherapy Endpoints 
and EORTC QOL Pal 15 and BM 22 questionnaires. Complete 
response was defined as a pain score of 0 at treated site with 
no concomitant increase in daily oral morphine equivalent 
(OMED). Partial response was defined as pain reduction of 2 
or more on a scale of 0 to 10 scales without analgesic 
increase, or analgesic reduction of 25% or more from baseline 
without an increase in pain. Pain progression as an increase 
in pain score of 2 or more above baseline with stable OMED, 
or an increase of 25% or more in OMED compared with 
baseline with the pain score stable or 1 point above baseline, 
and others were indeterminate. The study was registered on 
clinicaltrial.gov (NCT02376322) 
 
Results: Thirty patients were enrolled from 4 centres in 
Brazil, Italy and Canada during July 2014 to September 2015. 
There were 14 male and 16 female patients. The median age 
was 58 years old (range 26 - 79). Twenty-two (73%) had 
extraosseous soft tissue component, 4 neuropathic pain, 2 
post-surgical intervention, and 2 impending fracture in 
weight bearing bone. The most common primary cancer sites 
were breast (n = 7) and lung/prostate (n = 4 each). The most 
commonly irradiated areas were lumbosacral spine (n = 10), 
pelvis/hips (n = 8), thoracic spine (n = 7), cervical spine (n = 
3), and superficial bones (n = 2). The median pre-treatment 
worst pain score was 8 (range 1 to 10) and the median daily 
OMED was 40 mg (range 0 to 360). The median follow up was 
3.7 months (range 0.3 to 9.6). At 2 months, 20 patients were 
alive (66%). Eleven (55%) had complete or partial response, 4 
(20%) progressive disease and 5 (25%) indeterminate 
response. A statistically significant improvement (p < 0.0001) 
was seen in the painful sites and physical functioning for the 
BM22 while the other items in BM 22 and C15-PAL remained 
stable. No patient suffered from spinal cord compression or 
pathologic fracture, and re-irradiation was not required. 
 
Conclusion: The 2 fractions of radiotherapy with 8 Gy each 
one week apart appears to be well tolerated without serious 
side effects in patients with complicated bone metastases 
and poor performance status. QOL remained stable. The 
efficacy was similar in patients with uncomplicated bone 
metastases treated with hypofractionated radiotherapy. 
 
EP-1424  
Palliative short-course radiotherapy in rectal cancer: a 
phase II study. 
V. Picardi
1Fondazione di Ricerca e Cura “Giovanni Paolo II”- Catholic 
University of Sacred Heart, Radiotherapy Unit, Campobasso, 
Italy 
1, F. Deodato1, G. Macchia1, A. Guido2, L. 
Giaccherini2, M. Nuzzo1, L. Fuccio3, D. Cuicchi3, G. Ugolini3, 
A. Farioli3, S. Cilla4, F. Cellini5, S. Cammelli2, A.F.M.K. 
Uddin6, M.A. Gambacorta5, M. Buwenge2, T. Salah7, G. 
Poggioli3, V. Valentini5, A.G. Morganti2 
2S. Orsola-Malpighi Hospital- University of Bologna, Radiation 
Oncology Center- Department of Experimental- Diagnostic 
and Specialty Medicine - DIMES, Bologna, Italy 
3S. Orsola-Malpighi Hospital- University of Bologna, 
Department of Medical and Surgical Sciences - DIMEC, 
Bologna, Italy 
4Fondazione di Ricerca e Cura “Giovanni Paolo II”- Catholic 
University of Sacred Heart, Medical Physics Unit, 
Campobasso, Italy 
5Policlinico Universitario “A. Gemelli”- Catholic University of 
Sacred Heart, Department of Radiotherapy, Roma, Italy 
6United Hospital Limited, Department of Radiation Oncology, 
Gulshan- Dhaka, Bangladesh 
7Assiut University, Faculty of Medicine, Assiut, Egypt 
 
Purpose or Objective: The aim of this phase II study was to 
evaluate the symptomatic response rate of short course 
radiation therapy (SCRT) in patients with advanced rectal 
cancer not amenable for curative treatment and with 
obstructive symptoms. 
 
Material and Methods: Patients unfit for surgical resection 
due to synchronous metastases, age and/or comorbidities, 
were eligible. The sample size was calculated based on the 
two-stage design by Simon. SCRT was delivered with an 
isocentric four-field box technique (total dose: 25 Gy; 5 Gy 
per fraction in 5 days). No chemotherapy was allowed during 
SCRT. Clinical outcome measures were symptomatic response 
rate, toxicity, colostomy-free survival and overall survival. 
 
Results: From October 2003 to November 2012, 18 patients (4 
females and 14 males; mean age 77.5 years) were enrolled. 
The median follow up was 57 months (range: 23-132 months). 
Symptomatic response was: 5.5% no change, 66.7 % partial 
response, 27.8% complete response. No patients stopped 
treatment for gastrointestinal or genitourinary toxicities: 
27.8% patients had grade 1-2 toxicity and 16.7% had grade 3 
toxicity; only 1 patient had haematological grade 2 toxicity. 
One and 2-year colostomy-free survival were 100% and 71.4% 
(median: 30 months), respectively. Reduction/resolution of 
pain and bleeding was 87.5 % and 100 %, respectively. One 
and 2-year actuarial overall survival were 66.3% and 53% 
(median: 25 months), respectively. 
 
Conclusion: In this phase II study based on SCRT in patients 
with symptomatic rectal cancer not eligible for curative 
treatment an improvement of initial symptoms with 
